Evidence map›Paper›PMID 31668145›Full record

ArticleBosnian journal of basic medical sciences2020

The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.

Amina Kurtovic-Kozaric, Erna Islamagic, Hana Komic, Nurija Bilalovic, Izet Eminovic, Adnan Burekovic, Amna Uzunovic, Sabira Kurtovic

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bosnian journal of basic medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Amina Kurtovic-KozaricDepartment of Clinical Pathology, Cytology and Human Genetics, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina; Faculty of Science, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Erna IslamagicFaculty of Science, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Hana KomicFaculty of Science, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Nurija BilalovicDepartment of Clinical Pathology, Cytology and Human Genetics, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Izet EminovicFaculty of Science, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Adnan BurekovicDepartment of Internal Medicine, Clinical Hospital, Zenica, Bosnia and Herzegovina.
Amna UzunovicDepartment of Internal Medicine, Clinical Hospital, Zenica, Bosnia and Herzegovina.
Sabira KurtovicDepartment of Hematology, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
University of Sarajevo · BAUniversity of Zenica · BA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of mutually exclusive somatic mutations shared among myeloproliferative neoplasm (MPN) subtypes has provided a powerful tool for studying disease evolution. Clinical features, gene mutations, and survival over 18 years were analyzed in MPN patients. One hundred thirty-eight MPN patients were subcategorized according to MPN subtypes: essential thrombocythemia (ET, n = 41), polycythemia vera (PV, n = 56), primary myelofibrosis (PMF, n = 10), and MPN unclassified (MPN-U, n = 31). Patient characteristics included clinical parameters, overall survival (OS), and mutational status of the Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) genes. We compared hematologic and clinical features of JAK2V617F-ET vs. CALR-mutated ET vs. JAK2V617F-PV patients. JAK2V617F-patients had higher values of erythrocytes, hemoglobin, and hematocrit compared to CALR-mutated patients (p < 0.05). The mutant allele burden in JAK2V617F-PV and JAK2V617F-ET patients directly correlated with erythrocyte, hemoglobin, and hematocrit values, but it inversely correlated with platelet count. Thus, mutant allele burden was an indicator of the clinical phenotype in JAK2V617F-MPN patients. OS was not affected by the mutational status. In general, mutated JAK2, CALR, and MPL genes left specific hematological signatures.

Indexed as

PhenotypeAdultAgedAged, 80 and overBosnia and HerzegovinaCalreticulinFemaleFollow-Up StudiesHumansJanus Kinase 2MaleMiddle AgedMutationMyeloproliferative DisordersReceptors, ThrombopoietinSurvival RateCalreticulinCALR protein, humanJAK2 protein, humanJanus Kinase 2MPL protein, humanReceptors, Thrombopoietin

Identifiers

PMID31668145
PMCPMC7202189
OpenAlexW2982450219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.